Angelini Pharma, part of Angelini Industries, has entered a collaboration and licensing agreement with Quiver Bioscience.
The partnership aims to advance novel therapeutics for genetic epilepsies, including severe childhood-onset conditions.
Genetic epilepsies remain among the most challenging CNS disorders to treat. Despite recent advances:
This collaboration targets those gaps at their biological roots.
The partnership brings together complementary strengths. Quiver Bioscience contributes:
Angelini Pharma contributes:
The goal is to generate data sets of unprecedented depth and scale in epilepsy research.
A key focus area is Developmental and Epileptic Encephalopathies (DEEs).
DEEs are:
Although often caused by gene mutations, their functional and molecular consequences remain unclear in most cases. This limits effective drug development.
Quiver’s technology links neuronal function to molecular drivers.
Its platform:
The ultimate aim is to develop differentiated therapies capable of addressing multiple DEEs.
Under the multi-year agreement:
Payments are triggered upon Angelini’s selection of drug targets from the collaboration.
According to Angelini leadership, the deal supports long-term priorities.
It helps to:
The partnership follows several strategic acquisitions and collaborations over the past two years.
Quiver Bioscience is a technology-driven biotech focused on AI-enabled discovery for neurological diseases, translating functional neuronal data into precision medicines.
Angelini Pharma is an international pharmaceutical company focused on brain health, including mental health and epilepsy, as well as consumer health.
Angelini Industries, founded in 1919 in Ancona, operates across health, industrial technology, and consumer goods, with over 5,800 employees in 21 countries.
Bottom line: This collaboration pairs deep epilepsy expertise with next-generation AI discovery. If successful, it could unlock new treatment options for some of the most underserved genetic epilepsy patients.